Just as multiple drugs targeting amyloid-beta are set to read out Phase III results, a new Alzheimer's disease target, tau, is gaining popularity. Read More
In determining that the Affordable Care Act (ACA) was constitutional, the Supreme Court last week blew away a cloud of uncertainty that has been hanging over the biopharma industry for the past two years. But other clouds are gathering. Read More
There is no doubt that the biotechnology industry is now truly global. Approximately one-third of the delegates at the recent BIO 2012 International Convention in Boston came from countries outside of the U.S. A stroll through the convention's exhibition floor provided further evidence to the fact that emerging countries are placing their strategic bets on biotechnology to boost their economies. Read More
